PRN: Global Radiopharmaceuticals Market to Grow at a CAGR of 9% by 2021: Rising Burden of the Neurological Disorders

16/ago/2017 12:45:09 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Radiopharmaceuticals Market to Grow at a CAGR of 9% by 2021: Rising Burden of the Neurological Disorders


DUBLIN, August 16, 2017 /PRNewswire/ --

The "Global Radiopharmaceuticals Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global radiopharmaceuticals market to grow at a CAGR of 9.02% during the period 2017-2021.

The report, Global Radiopharmaceuticals Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is partnerships for development of radiopharmaceuticals. Some of the leading nuclear medicines and nuclear imaging companies are forming partnerships to solve long-standing radiopharmaceutical concerns in medical imaging and increase their market share. These partnerships will increase the production of low-cost radiopharmaceuticals, which will boost the growth of the market.

According to the report, one of the major drivers for this market is the rising burden of the neurological disorders. Neurological disorders are diseases that are related to the brain, spine, and the nerves. There are over 600 diseases of the nervous system, some of the most common diseases are epilepsy, Parkinson's disease, brain tumors, and stroke; while some of the less familiar ones include frontotemporal dementia.

Further, the report states that one of the major factors hindering the growth of this market is the shortage of radioisotopes. Mo-99 is a precursor of Tc-99, and its half-life is 66 hours, which after decaying, forms Tc-99. It emits gamma rays, which help clinicians create images for diagnosis and monitor the spread of disease. Tc-99 is used in more than 40 million imaging procedures globally, which covers around 72% of all procedures in nuclear medicine. However, shortage of few important radioisotopes such as Mo-99 has an adverse effect on the global radiopharmaceuticals market.

Key vendors

  • Bayer,
  • Cardinal Health,
  • GE Healthcare,
  • Lantheus Medical Imaging

Other prominent vendors

  • ABT Molecular Imaging
  • Advanced Accelerator Applications
  • Algeta
  • Eczacibasi-Monrol Nuclear Products
  • FUJIFILM Holdings
  • Isologic Innovative Radiopharmaceuticals
  • Nordion
  • Piramal Imaging
  • RadioMedix
  • Triad Isotopes

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Pipeline Analysis

Part 07: Market Segmentation By Application

Part 08: Geographical Segmentation

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Key Vendor Analysis

Part 14: Appendix

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl